A Double-Blind, Randomized Controlled Trial of Ethyl-Eicosapentaenoate for Major Depressive Disorder
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To examine the efficacy and tolerability of ethyl-eicosapentaenoate (EPA-E) monotherapy for major depressive disorder (MDD). METHOD: Fifty-seven adults with DSM-IV MDD were randomly assigned from January 2003 until June 2006 to receive 1 g/d of eicosapentaenoic acid (EPA) or placebo for 8 weeks in a double-blind, randomized, controlled pilot study. Response criteria were on the basis of the 17-item Hamilton Depression Rating Scale (HDRS-17). Subjects' plasma lipid profiles were examined by gas chromatography. RESULTS: Thirty-five subjects (63% female; mean +/- SD age = 45 +/- 13 years) were eligible for the intent-to-treat (ITT) analysis. In the ITT sample, mean +/- SD HDRS-17 scores decreased from 21.6 +/- 2.7 to 13.9 +/- 8.9 for the EPA group (n = 16) and from 20.5 +/- 3.6 to 17.5 +/- 7.5 for the placebo group (n = 19) (P = .123); the effect size for EPA was 0.55. ITT response rates were 38% (6/16) for EPA, and 21% (4/19) for placebo (P = .45). Among the 24 study completers, mean +/- SD HDRS-17 scores decreased from 21.3 +/- 3.0 to 11.1 +/- 8.1 for the EPA group and from 20.5 +/- 3.8 to 16.3 +/- 6.9 for the placebo group (P = .087); the effect size for EPA was 0.73. Completer response rates were 45% (5/11) for EPA, and 23% (3/13) for placebo (P = .39). Among EPA subjects, baseline n-6/n-3 ratio was associated with decrease in HDRS-17 score (r = -0.686, P = .030) and with treatment response (P = .032); change in n-6/n-3 ratio was associated with change in HDRS-17 score (r = .784, P = .032). Side effects, reported in 2 EPA subjects and 5 placebo subjects, were exclusively gastrointestinal, mild, and not associated with discontinuation. CONCLUSIONS: EPA demonstrated an advantage over placebo that did not reach statistical significance, possibly due to the small sample and low completer rates, which were the major study limitations. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00096798.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Resolution of inflammation: the beginning programs the end
Serhan, C. N., & Savill, J. (2005) · Nature Immunology · doi:10.1038/ni1276 · Cited by 2,552
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
Wilamowska (2010) · doi:10.1001/archpsyc.1988.01800320058007 · Cited by 2,115
Serhan, C. N., Hong, S., Gronert, K., Colgan, S. P., Devchand, P. R., Mirick, G., & Moussignac, R.-L. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020760 · Cited by 1,650
Distribution, interconversion, and dose response of n-3 fatty acids in humans.
Arterburn, L. M., Hall, E. B., & Oken, H. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1467s · Cited by 1,162
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109
Omega-3 Fatty Acids: Evidence Basis for Treatment and Future Research in Psychiatry
Freeman, M. P., Hibbeln, J. R., Wisner, K. L., Davis, J. M., Mischoulon, D., Peet, M., Keck, P. E., Marangell, L. B., Richardson, A. J., Lake, J., et al. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1217 · Cited by 709
Self-citationNemets, B., Stahl, Z., & Belmaker, R. H. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.477 · Cited by 627
Lin, P.-Y., & Su, K.-P. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0712 · Cited by 481
Cited by
Grosso, G., Pajak, A., Marventano, S., Castellano, S., Galvano, F., Bucolo, C., Drago, F., & Caraci, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096905 · Cited by 449
“Among them, 11 trials were conducted in patients with a DSM-defined diagnosis of MDD, including 8 studies conducted in adults [46,48,70,76–78,83,84] and 3 studies in elderly patients [53,95,96].”
MethodMeta-Analysis of the Effects of Eicosapentaenoic Acid (EPA) in Clinical Trials in Depression
Sublette, M. E., Ellis, S. P., Geant, A. L., & Mann, J. J. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06634 · Cited by 417
Efficacy of omega-3 PUFAs in depression: A meta-analysis
Liao, Y., Xie, B., Zhang, H., He, Q., Guo, L., Subramanieapillai, M., Fan, B., Lu, C., & McIntyre, R. S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0515-5 · Cited by 404
Diet, Stress and Mental Health
Bremner, J., Moazzami, K., Wittbrodt, M., Nye, J., Lima, B., Gillespie, C., Rapaport, M., Pearce, B., Shah, A., & Vaccarino, V. (2020) · Nutrients · doi:10.3390/nu12082428 · Cited by 377
Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis
Bloch, M. H., & Hannestad, J. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.100 · Cited by 293
Mocking, R. J. T., Harmsen, I., Assies, J., Koeter, M. W. J., Ruhé, H. G., & Schene, A. H. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.29 · Cited by 279
Shelton, R. C., & Miller, A. H. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.04.004 · Cited by 261
Bai, S., Guo, W., Feng, Y., Deng, H., Li, G., Nie, H., Guo, G., Yu, H., Ma, Y., Wang, J., et al. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-320912 · Cited by 235
Antioxidants as potential therapeutics for neuropsychiatric disorders
Pandya, C. D., Howell, K. R., & Pillai, A. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.10.017 · Cited by 222
“…udy EPA demonstrated an advantage over placebo in 17-item Hamilton Depression Rating Scale (HDRS-17), but not statistically significant Mischoulon et al. (2009) nd pilot Significant effects of omega-3 on symptoms using the CDRS, CDI, and CGI Q8Nemets et al. (2006) ontrolled No…”
Omega-3 fatty acids for depression in adults
Appleton, K. M., Sallis, H. M., Perry, R., Ness, A. R., & Churchill, R. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004692.pub4 · Cited by 180
The importance of n-6/n-3 fatty acids ratio in the major depressive disorder
Husted, K. S., & Bouzinova, E. V. (2016) · Medicina · doi:10.1016/j.medici.2016.05.003 · Cited by 142
“Since an elevated ratio between omega-6 and omega-3 PUFAs was observed among depressive patients [19–24] and MDD is associated with increased production of pro-inflammatory cytokines [70–73], it seems reasonable to suspect the correlation between high omega-6/ omega-3 ratio, low-grade inflammation, and depression.”
BackgroundInfluentialVan Dael, P. (2021) · Nutrition Research and Practice · doi:10.4162/nrp.2021.15.2.137 · Cited by 138
“Several lines of evidence have suggested the efficacy of n-3 LCPUFA as a MDD risk reduction or dietary management strategy in epidemiological and case-controlled studies [98,99], randomized-controlled trials [100-110], and meta-analyses [111-120].”
BackgroundChang, C.-H., Tseng, P.-T., Chen, N.-Y., Lin, P.-C., Lin, P.-Y., Chang, J. P. C., Kuo, F.-Y., Lin, J., Wu, M.-C., & Su, K.-P. (2018) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2018.01.001 · Cited by 103
Omega-3 fatty acids for depression in adults
Appleton, K. M., Voyias, P. D., Sallis, H. M., Dawson, S., Ness, A. R., Churchill, R., & Perry, R. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004692.pub5 · Cited by 84
Acute EPA-induced learning and memory impairment in mice is prevented by DHA
Liu, J.-H., Wang, Q., You, Q.-L., Li, Z.-L., Hu, N.-Y., Wang, Y., Jin, Z.-L., Li, S.-J., Li, X.-W., Yang, J.-M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19255-1 · Cited by 77
Liu, J. J., Galfalvy, H. C., Cooper, T. B., Oquendo, M. A., Grunebaum, M. F., Mann, J. J., & Sublette, M. E. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m07970 · Cited by 73
Metadata
- Authors
- Mischoulon, D., Papakostas, G. I., Dording, C. M., Farabaugh, A. H., Sonawalla, S. B., Agoston, A. M., Smith, J., Beaumont, E. C., Dahan, L. E., Alpert, J. E., Nierenberg, A. A., & Fava, M.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2009-08-25
- Volume
- 70
- Issue
- 12
- Pages
- 1636-1644
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2042223411
- Cited by
- 94
- References
- 17
- FWCI
- 6.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.